Nath Bio-Genes (India) financials

·FMCG & RetailChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹328cr+15.8% on Q1 FY26
Net profit
₹32.3cr−13.5% on Q1 FY26
EBITDA margin
10.7%−2.8 pts on Q1 FY26
EPS
₹16.98−13.3% on Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue328284+15.8%
EBITDA35.238.3−8.2%
EBITDA margin10.7%13.5%−2.8 pts
Profit before tax33.037.9−13.1%
Net profit32.337.3−13.5%
EPS₹16.98₹19.58−13.3%

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹328 crNet profit₹32.3 crNet margin9.8%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
252————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
76.076.088.977.438.0
139139123105105
314————
490445365333301
—+22.0%+9.7%+10.4%—
49.352.449.849.948.7
10.1%11.8%13.7%15.0%16.2%
45.348.546.046.645.7
36.641.638.639.635.0
7.5%9.4%10.6%11.9%11.6%
₹19.26₹21.91₹20.31₹20.85₹18.43
—+7.9%−2.6%+13.1%—
—−12.617.670.338.4
—−3.0−7.9−8.4−2.5
−15.6−15.69.761.935.8
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

NATHBIOGEN₹132.38

Nath Bio-Genes (India) Limited

· FMCG & Retail
₹ CrorePeersSARVESHWARINDOUSSUKHJITSKOHINOORAGRITECHREGAALBSHSLGULPOLYMcap ₹252 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————251.6
- Cash, Equiv & ST Investments38.077.488.976.076.0
+ Total Debt105.2105.5122.5138.5138.5
Enterprise Value————314.1
Revenue301.4332.6364.9445.1489.8
Growth %, YoY—+10.4+9.7+22.0—
EBITDA48.749.949.852.449.3
Margin %16.1714.9913.6511.7810.07
EBIT45.746.646.048.545.3
Net Income35.039.638.641.636.6
Margin %11.6211.9110.589.357.47
EPS, Adj (current shares)18.4320.8520.3121.9119.26
Growth %, YoY—+13.1-2.6+7.9—
Cash from Operations38.470.317.6-12.6—
Capital Expenditures-2.5-8.4-7.9-3.0—
Free Cash Flow35.861.99.7-15.6-15.6
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Nath Bio-Genes financials and key ratios

Prices at the previous close · figures from the company's filings with NSE

Nath Bio-Genes (NSE: NATHBIOGEN) had a market capitalisation of ₹252 crore at the previous close (₹132.38 a share), a PE ratio of 6.9 on the last four quarters' profit and a price-to-book ratio of 0.37. In FY26 its consolidated net profit was ₹41.6 crore on revenue of ₹445 crore; in Q1 FY27 (April–June 2026) it was ₹32.3 crore, down 13.5% year on year. Its debt-to-equity ratio was 0.20 on 31 March 2026. Promoters held 45.60% of the shares on 30 September 2026.

Share price used
₹132.38 · previous close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

Nath Bio-Genes at a glance · consolidated

Market cap
₹252 Crat ₹132.38 · previous close
PE ratio (last 4 quarters)
6.96.0 on FY26 profit
Price to book (PB)
0.37book value ₹358.06 a share
ROE (FY26)
6.3%+0.1 pts vs FY25ROCE 7.1%
Debt to equity
0.20net debt ₹62.5 Cr
Promoter holding
45.60%unchanged vs 30 Jun 202630 September 2026
Dividend yield
1.51%₹2 a share in 12 months
Net worth
₹680 Cr+5.6% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
−₹15.6 Cr

Questions

What is the Nath Bio-Genes PE ratio today?

Nath Bio-Genes' PE ratio is 6.9 at the previous close (₹132.38 a share): a market capitalisation of ₹252 crore divided by consolidated net profit of ₹36.6 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹41.6 crore) it is 6.0.

What is the Nath Bio-Genes debt to equity ratio?

Nath Bio-Genes' debt-to-equity ratio was 0.20 on 31 March 2026: borrowings of ₹139 crore against total equity of ₹680 crore. A year earlier, on 31 March 2025, it was 0.19.

What is the Nath Bio-Genes net worth?

Nath Bio-Genes' net worth — shareholders' equity in its consolidated balance sheet — was ₹680 crore on 31 March 2026, up 5.6% from ₹644 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹252 crore at the previous close.

What is the Nath Bio-Genes PB ratio (price to book value)?

Nath Bio-Genes' price-to-book (PB) ratio is 0.37 at the previous close: a market capitalisation of ₹252 crore divided by shareholders' equity (book value) of ₹680 crore on 31 March 2026. That is a book value of ₹358.06 per share against a share price of ₹132.38.

What is the Nath Bio-Genes ROE and ROCE?

In FY26, Nath Bio-Genes' return on equity (ROE) was 6.3% and its return on capital employed (ROCE) was 7.1%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 6.2% and ROCE 7.2%.

What is the Nath Bio-Genes book value per share?

Nath Bio-Genes' book value per share was ₹358.06 on 31 March 2026: shareholders' equity of ₹680 crore divided by the 1.9 crore shares in issue, up 5.6% from ₹339.08 a year earlier. The share price at the previous close was ₹132.38.

What is the Nath Bio-Genes market cap?

Nath Bio-Genes' market capitalisation was ₹252 crore at the previous close: 1.9 crore shares at ₹132.38 each.

What is the Nath Bio-Genes EPS?

Nath Bio-Genes' basic earnings per share (EPS) were ₹20.98 in FY26, against ₹20.14 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹18.43.

What is the Nath Bio-Genes dividend in 2026 and its record date?

In 2026, Nath Bio-Genes has declared one dividend: ₹2 with record date 11 September 2026.

Is Nath Bio-Genes debt free?

No. Nath Bio-Genes had borrowings of ₹139 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.20. Its cash and current investments were ₹76 crore, so its net debt was ₹62.5 crore.

What is the Nath Bio-Genes dividend yield?

Nath Bio-Genes' dividend yield is 1.51% at the previous close: dividends of ₹2 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹132.38. They were ₹2 on 11 September 2026.

What is the Nath Bio-Genes promoter holding?

Promoters held 45.60% of Nath Bio-Genes on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.

What is the Nath Bio-Genes shareholding pattern?

On 30 September 2026, Nath Bio-Genes' shares were held by promoters 45.60%, foreign portfolio investors (FII/FPI) 0.19%, domestic institutions (DII) 0.01% (including mutual funds at 0.01%) and retail and other non-institutional investors 54.21%. Over the year, FII holding was down 0.13 percentage points from 0.32% and DII holding was down 0.75 percentage points from 0.76%.

What are the Nath Bio-Genes latest quarterly results?

Nath Bio-Genes' latest results are for Q1 FY27 (April–June 2026), filed on 29 July 2026: consolidated net profit ₹32.3 crore, down 13.5% from ₹37.3 crore in Q1 FY26; revenue from operations ₹328 crore, up 15.8% year on year.

What is the Nath Bio-Genes revenue and profit in FY26?

In FY26 (April 2025–March 2026), Nath Bio-Genes' consolidated net profit was ₹41.6 crore, up 7.9% from ₹38.6 crore in FY25, on revenue from operations of ₹445 crore (up 22.0%). Over three years, from FY23, net profit was up 18.9%.

What is the Nath Bio-Genes free cash flow?

In FY26, Nath Bio-Genes generated ₹12.6 crore of cash from operations and spent ₹3 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹15.6 crore. In FY25 it was ₹9.7 crore.

When are the Nath Bio-Genes next results?

Nath Bio-Genes has not yet announced the date of its Q2 FY27 results (July–September 2026); under SEBI's listing rules (Regulation 33) they are due by 14 November 2026.

Nath Bio-Genes vs Sarveshwar Foods: how do they compare?

In FY26, Nath Bio-Genes earned net profit of ₹41.6 crore on revenue of ₹445 crore, against ₹31.8 crore on ₹1,346 crore for Sarveshwar Foods. Nath Bio-Genes' operating margin was 10.9% (Sarveshwar Foods 4.8%) and its return on equity 6.3% (Sarveshwar Foods 8.1%).

How does Nath Bio-Genes compare with its peers?

On FY26 consolidated figures, against Sarveshwar Foods, Indo Us Biotech and Sukhjit Starch & Chemicals: Nath Bio-Genes' operating margin of 10.9% is the second highest of the four (Sarveshwar Foods 4.8%, Indo Us Biotech 14.6%, Sukhjit Starch & Chemicals 3.4%; peer average 7.6%); its return on equity of 6.3% is the third highest of the four (Sarveshwar Foods 8.1%, Indo Us Biotech 15.3%, Sukhjit Starch & Chemicals 4.9%; peer average 9.4%).

Where do these Nath Bio-Genes figures come from?

From Nath Bio-Genes' own consolidated results, balance sheets and shareholding patterns filed with NSE. Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.